<p>Prime Medicine, Inc.（紐約證券交易所代碼：PRME - 獲取免費報告）在目前覆蓋該股票的八位分析師中被評為 “適度買入”，Marketbeat 報道。三位股票研究分析師給予該股票持有評級，四位給予買入評級，一位給予強烈買入評級。在過去一年中，覆蓋該股票的經紀公司平均一年目標價為 9.2083 美元。</p>
<ul>
<li>2 只基因編輯股票值得關注，列入 2024 年觀察名單</li>
</ul>
<p>多家經紀公司最近對 PRME 發表了看法。Wedbush 在 11 月 10 日的研究報告中重申了 “跑贏大盤” 的評級，並對 Prime Medicine 的股票設定了 8.00 美元的目標價。花旗集團在 11 月 11 日的研究報告中將 Prime Medicine 的目標價從 5.00 美元下調至 4.25 美元，並對該股票設定了 “中性” 評級。最後，Chardan Capital 在 11 月 10 日的報告中將 Prime Medicine 的目標價從 10.00 美元下調至 9.00 美元，並對該公司設定了 “買入” 評級。</p>
<p>獲取 <strong>Prime Medicine</strong> 警報：</p>
<p><strong>閲讀我們關於 PRME 的最新報告</strong></p>
<h2>Prime Medicine 價格表現</h2>
<p>紐約證券交易所 PRME 週三開盤價為 3.72 美元。該公司的 50 日移動平均價格為 4.92 美元，200 日移動平均價格為 3.65 美元。公司市值為 6.715 億美元，市盈率為-1.81，貝塔值為 2.64。Prime Medicine 的 1 年最低價為 1.11 美元，1 年最高價為 6.94 美元。</p>
<h2>機構投資者對 Prime Medicine 的看法</h2>
<p>多家機構投資者和對沖基金最近買入和賣出了 PRME 的股票。Levin Capital Strategies L.P.在第二季度將其在 Prime Medicine 的持股增加了 300.0%。Levin Capital Strategies L.P.現在擁有 140,000 股該公司的股票，價值 346,000 美元，此前在上個季度增持了 105,000 股。Palumbo Wealth Management LLC 在第二季度將其在 Prime Medicine 的股份增加了 92.1%。Palumbo Wealth Management LLC 現在擁有 183,358 股該公司的股票，價值 453,000 美元，此前在上個季度增持了 87,896 股。Vanguard Personalized Indexing Management LLC 在第二季度將其在 Prime Medicine 的持股增加了 52.2%。Vanguard Personalized Indexing Management LLC 現在擁有 23,191 股該公司的股票，價值 57,000 美元，此前在上個季度增持了 7,954 股。Ieq Capital LLC 在第一季度購買了 Prime Medicine 的新股份，價值約 69,000 美元。最後，紐約梅隆銀行在第一季度將其在 Prime Medicine 的持股增加了 20.4%。紐約梅隆銀行現在擁有 155,992 股該公司的股票，價值 310,000 美元，此前在上個季度增持了 26,478 股。對沖基金和其他機構投資者持有該公司 70.37% 的股份。</p>
<h2>關於 Prime Medicine</h2>
<p>（獲取免費報告）</p>
<p>Prime Medicine, Inc.是一家生物技術公司，通過部署基因編輯技術提供遺傳療法，以應對各種疾病。該公司提供 Prime Editors，包含 Cas 蛋白和逆轉錄酶的融合體的 Prime Editor 蛋白；以及 pegRNA，旨在將 Prime Editor 定位到特定的基因組位置，併為對目標 DNA 序列進行所需編輯提供模板。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Prime Medicine</li>
<li>在 52 周高點盈利交易股票</li>
<li>華納兄弟出售傳聞升温：投資者需要知道的事項</li>
<li>能源和石油股票解析</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
<li>何時出售股票以獲利或虧損</li>
<li>標普 500 在 12 月會反彈嗎？這三個信號指向重大變動</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
<p>在考慮 Prime Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Prime Medicine 並不在名單上。</p>
<p>雖然 Prime Medicine 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRME

<p>Prime Medicine, Inc.（紐約證券交易所代碼：PRME）獲得了八位分析師的共識 “適度買入” 評級。該股票的 1 年目標價格平均為 9.2083 美元。最近的分析師行動包括 Wedbush 的 “跑贏大盤” 評級，目標價為 8 美元，花旗集團的 “中性” 評級，目標價為 4.25 美元，以及 Chardan Capital 的 “買入” 評級，目標價為 9 美元。機構投資者增加了持股，對沖基金持有該股票的 70.37%。Prime Medicine 專注於利用基因編輯技術進行基因療法</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the eight analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.2083.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（紐約證券交易所代碼：PRME - 獲取免費報告）在目前覆蓋該股票的八位分析師中被評為 “適度買入”，Marketbeat 報道。三位股票研究分析師給予該股票持有評級，四位給予買入評級，一位給予強烈買入評級。在過去一年中，覆蓋該股票的經紀公司平均一年目標價為 9.2083 美元。</p>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因編輯股票值得關注，列入 2024 年觀察名單</li>
</ul>
</div><p>A number of brokerages have recently weighed in on PRME. Wedbush restated an &#34;outperform&#34; rating and issued a $8.00 price target on shares of Prime Medicine in a research report on Monday, November 10th. Citigroup lowered their price objective on shares of Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a research note on Tuesday, November 11th. Finally, Chardan Capital dropped their target price on shares of Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating for the company in a report on Monday, November 10th.</p>
<div class="lb-trans"><p>多家經紀公司最近對 PRME 發表了看法。Wedbush 在 11 月 10 日的研究報告中重申了 “跑贏大盤” 的評級，並對 Prime Medicine 的股票設定了 8.00 美元的目標價。花旗集團在 11 月 11 日的研究報告中將 Prime Medicine 的目標價從 5.00 美元下調至 4.25 美元，並對該股票設定了 “中性” 評級。最後，Chardan Capital 在 11 月 10 日的報告中將 Prime Medicine 的目標價從 10.00 美元下調至 9.00 美元，並對該公司設定了 “買入” 評級。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Prime Medicine</strong> 警報：</p>
</div><p><strong>Read Our Latest Report on PRME</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 PRME 的最新報告</strong></p>
</div><h2>Prime Medicine Price Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 價格表現</h2>
</div><p>NYSE PRME opened at $3.72 on Wednesday. The business has a 50 day moving average price of $4.92 and a 200 day moving average price of $3.65. The company has a market capitalization of $671.50 million, a P/E ratio of -1.81 and a beta of 2.64. Prime Medicine has a 1-year low of $1.11 and a 1-year high of $6.94.</p>
<div class="lb-trans"><p>紐約證券交易所 PRME 週三開盤價為 3.72 美元。該公司的 50 日移動平均價格為 4.92 美元，200 日移動平均價格為 3.65 美元。公司市值為 6.715 億美元，市盈率為-1.81，貝塔值為 2.64。Prime Medicine 的 1 年最低價為 1.11 美元，1 年最高價為 6.94 美元。</p>
</div><h2>Institutional Investors Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>機構投資者對 Prime Medicine 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of PRME. Levin Capital Strategies L.P. raised its holdings in shares of Prime Medicine by 300.0% in the second quarter. Levin Capital Strategies L.P. now owns 140,000 shares of the company's stock worth $346,000 after acquiring an additional 105,000 shares during the last quarter. Palumbo Wealth Management LLC boosted its stake in shares of Prime Medicine by 92.1% during the second quarter. Palumbo Wealth Management LLC now owns 183,358 shares of the company's stock valued at $453,000 after acquiring an additional 87,896 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in Prime Medicine by 52.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 23,191 shares of the company's stock worth $57,000 after purchasing an additional 7,954 shares in the last quarter. Ieq Capital LLC purchased a new stake in Prime Medicine during the 1st quarter worth about $69,000. Finally, Bank of New York Mellon Corp raised its stake in Prime Medicine by 20.4% in the 1st quarter. Bank of New York Mellon Corp now owns 155,992 shares of the company's stock valued at $310,000 after purchasing an additional 26,478 shares during the last quarter. Hedge funds and other institutional investors own 70.37% of the company's stock.</p>
<div class="lb-trans"><p>多家機構投資者和對沖基金最近買入和賣出了 PRME 的股票。Levin Capital Strategies L.P.在第二季度將其在 Prime Medicine 的持股增加了 300.0%。Levin Capital Strategies L.P.現在擁有 140,000 股該公司的股票，價值 346,000 美元，此前在上個季度增持了 105,000 股。Palumbo Wealth Management LLC 在第二季度將其在 Prime Medicine 的股份增加了 92.1%。Palumbo Wealth Management LLC 現在擁有 183,358 股該公司的股票，價值 453,000 美元，此前在上個季度增持了 87,896 股。Vanguard Personalized Indexing Management LLC 在第二季度將其在 Prime Medicine 的持股增加了 52.2%。Vanguard Personalized Indexing Management LLC 現在擁有 23,191 股該公司的股票，價值 57,000 美元，此前在上個季度增持了 7,954 股。Ieq Capital LLC 在第一季度購買了 Prime Medicine 的新股份，價值約 69,000 美元。最後，紐約梅隆銀行在第一季度將其在 Prime Medicine 的持股增加了 20.4%。紐約梅隆銀行現在擁有 155,992 股該公司的股票，價值 310,000 美元，此前在上個季度增持了 26,478 股。對沖基金和其他機構投資者持有該公司 70.37% 的股份。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>關於 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.是一家生物技術公司，通過部署基因編輯技術提供遺傳療法，以應對各種疾病。該公司提供 Prime Editors，包含 Cas 蛋白和逆轉錄酶的融合體的 Prime Editor 蛋白；以及 pegRNA，旨在將 Prime Editor 定位到特定的基因組位置，併為對目標 DNA 序列進行所需編輯提供模板。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li>
<li>Energy and Oil Stocks Explained</li>
<li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Will the S&amp;P 500 Rally in December? These 3 Signals Point to a Big Move Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Prime Medicine</li>
<li>在 52 周高點盈利交易股票</li>
<li>華納兄弟出售傳聞升温：投資者需要知道的事項</li>
<li>能源和石油股票解析</li>
<li>從科學項目到溶劑：WeRide 的 761% 收入激增</li>
<li>何時出售股票以獲利或虧損</li>
<li>標普 500 在 12 月會反彈嗎？這三個信號指向重大變動</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=PRME"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Prime Medicine 嗎？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Prime Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Prime Medicine 並不在名單上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prime Medicine 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Prime Medicine, Inc. (NYSE:PRME) 獲得分析師的平均推薦評級為 “適度買入”